Key facts
- Type: Prescription Drug Abuse · Sedative-hypnotic misused
- Category: Prescription Drug Abuse
- Legal status in Kenya: Illegal. Scheduled under the Narcotic Drugs and Psychotropic Substances Act.
- Addiction risk: Very high
- Source: Illicit manufacture; smuggled from India and South Africa
NACADA Helpline: 1192 | If you or someone you know needs help with substance use, call the National Authority for the Campaign Against Alcohol and Drug Abuse. Free, confidential, available 24 hours.
Overview
What is Mandrax (Methaqualone)?
Mandrax (methaqualone) was originally manufactured as a prescription sedative and sleeping tablet in the 1950s and 1960s. It was withdrawn from medical use worldwide in the 1970s because of its extreme abuse potential. It is now produced entirely illicitly, primarily in India and South Africa.
In Southern and East Africa it is commonly smoked through a “white pipe”: the mandrax tablet is crumbled, mixed with cannabis, and smoked through a broken bottle neck. This method of administration is distinctive and deeply embedded in substance abuse culture in the region.
In Kenya, mandrax is documented primarily in Mombasa and coastal areas, where it arrives via maritime trafficking routes from South Asia and Southern Africa. NACADA includes it in its list of drugs of concern.
What it does to the brain and body
How does it work?
Methaqualone works similarly to barbiturates, enhancing GABA activity and suppressing the central nervous system. It produces a powerful sedation with a disinhibiting, euphoric phase before the sedation sets in. The combination of euphoria, disinhibition, and eventual deep sedation is the experience users seek.
Why people use it
What draws people to it?
The combination of an initial euphoric, disinhibiting phase followed by deep sedation creates an experience that users find intensely pleasurable.
Smoking mandrax mixed with cannabis creates a complex experience that combines sedation, euphoria, and the effects of cannabis.
Among long-term polydrug users, it is used as an add-on to intensify other drug experiences.
Short-term effects
What happens when someone uses it?
These effects can occur even with first-time or occasional use.
- Initial euphoria and disinhibition
- Deep sedation and loss of coordination
- Slurred speech and impaired memory
- Nausea and vomiting
- In combination with alcohol: risk of severe respiratory depression and death
Long-term effects
What happens with regular or prolonged use?
These effects build gradually and many are not reversible once they develop.
- Physical and psychological dependence
- Liver damage
- Peripheral nerve damage (numbness and weakness)
- Significant cognitive impairment
- Lung damage from smoking (when used as white pipe)
Recognising a problem
Signs that use may have become a problem
These signs apply to the person using the substance and can also help family members or friends recognise when help is needed.
- Use of a distinctive broken-bottle or improvised pipe for smoking
- Deep, difficult-to-wake sedation after use
- Obtaining mandrax or asking others about obtaining it
- Agitation and insomnia when unable to access it
Addiction and dependence
How addictive is it?
Very high addiction risk
Mandrax has very high abuse potential, which is why it was removed from legitimate medical use worldwide. Physical dependence and severe withdrawal develop with regular use.
Withdrawal from methaqualone can cause seizures and is medically dangerous. Medical supervision is essential.
Overdose and acute danger
When does it become immediately dangerous?
Seek emergency help immediately
if you see any of these signs in someone who has used this substance.
- Breathing that stops or becomes very slow
- Loss of consciousness
- Muscle twitching and seizures
- Combination with alcohol dramatically increases all risks
- Call 999 immediately for any suspected mandrax overdose.
Withdrawal
What happens when someone tries to stop?
Mandrax withdrawal can be life-threatening, including seizures and cardiovascular complications. It should be managed in a medical setting. Never stop suddenly after heavy regular use without medical supervision.
Who is most affected
Groups particularly at risk in Kenya
Long-term polydrug users in coastal Kenya (Mombasa, Malindi) are the primary documented users.
In South Africa, mandrax use is particularly prevalent in Cape Town’s Cape Flats communities, often in the “white pipe” combination with cannabis.
In Kenya
What the data says about Kenya
Mandrax is listed in NACADA’s surveillance documents as a drug of concern in Kenya, with primary documentation from the coast where maritime trafficking routes bring it in.
Its combination with cannabis in the white pipe method is particularly dangerous because the high temperatures involved release toxic combustion products, and the combination of mandrax and cannabis creates an unpredictable sedative effect.
Across East and Central Africa
How is it used in the wider region?
Names, availability, and prevalence vary by country. All data is drawn from government and academic sources.
| Country | Local name(s) | Context and notes |
|---|---|---|
| South Africa | Buttons, White pipe, Mandrax | South Africa has the most significant mandrax problem in Africa. Cape Town’s Cape Flats have documented endemic white pipe use. Illicitly manufactured tablets from India are trafficked through southern African ports. |
| Mozambique | Mandrax, Mandies | Significant transit country for mandrax from India. Domestic use also documented in Maputo. |
| Tanzania | Mandrax, Spoor | Trafficking documented through Dar es Salaam port. Local use present but less documented than in Southern Africa. |
Getting help
Where to turn in Kenya
NACADA Helpline
Free, confidential counselling and referral to treatment centres near you. Available 24 hours a day. 1192
Mathari National Hospital
Kenya's main national psychiatric and substance use treatment facility in Nairobi. Inpatient and outpatient services. 020 2714148
County referral hospitals
Every county in Kenya has a mental health and substance use service. Ask at your nearest hospital or health centre.
NACADA Helpline
For referral to a treatment centre experienced in managing sedative dependence. 1192
Sources
References
- National Authority for the Campaign Against Alcohol and Drug Abuse (NACADA). (2019). Trends and Patterns of Emerging Drugs in Kenya. Nairobi: NACADA.
- National Authority for the Campaign Against Alcohol and Drug Abuse (NACADA). (2021). Assessment of Emerging Trends of Drugs and Substance Abuse in Kenya 2021. Nairobi: NACADA.
- UNODC. (2023). World Drug Report 2023. Vienna: UNODC.